Mycotopia Therapies Partners with Public Policy Specialist PsychedelicsEUROPE to Explore Opportunities in the European Market
02 mai 2022 08h30 HE
|
Mycotopia Therapies Inc.
MIAMI, May 02, 2022 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc. (OTC Pink: TPIA) (the “Company”), a biopharma company focused on research, technology, and the development of medical psychedelics,...
Core One Labs’ Upgrades to OTCQB Venture Market
06 avr. 2022 08h30 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, April 06, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: “COOL”), (OTCQB: “CLABF”), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) a life sciences...
Core One Labs’ Akome Receives Positive Results from Bioassay Studies
02 avr. 2022 08h55 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, April 02, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that...
Core One’s Vocan Biotechnologies and Awakened Biosciences Collaborate to Advance Vocan’s Mass Production Capabilities
15 mars 2022 04h00 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, March 15, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that...
Core One Labs Proceeds with Next Milestone Achievement: To Produce Psilocybin
12 mars 2022 19h25 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, March 12, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that...
Core One Labs Announces Successful Proof-of-Concept for Biosynthetic N-methyltryptamine (NMT)
03 mars 2022 03h00 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, March 03, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”), is pleased to announce that...
Core One Labs Completes Strategic Acquisition of Awakened Biosciences and its Game-Changing Provisional Patents
11 févr. 2022 03h00 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”), a life sciences...
Core One Labs Expects Imminent Breakthrough to Produce NMT, Precursor to DMT
10 févr. 2022 03h00 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that,...
Core One Labs’ Successful Patent Application Filing for Protection of its Biosynthetic Production System for Psilocybin Marks a Significant Milestone for the Progression of Psychedelic Health Care
09 févr. 2022 03h00 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that...
Core One Labs’ Akome Biotech Signs Research Agreement with University of Barcelona, Faculty of Pharmacy and Food Sciences
26 janv. 2022 02h55 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that...